ClinicalTrials.gg
CompletedNCT03570554Updated Jun 19, 2020Results posted

A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale

A Phase 2 interventional study of Naproxen Sodium (Aleve, BAY117031) and Acetaminophen ER in Osteoarthritis, Knee, sponsored by Bayer. Completed at 5 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-06-19.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 11 studies testing acetaminophen in Osteoarthritis, Knee — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis, Knee.

Enrollment
9th of 11
41 · median 300
Started
2018
the only one that year
Phase 2
Only one
of the 11
Registered
9th of 11
by date
Lead sponsor
1 of 11
Bayer

Among the 11 studies testing acetaminophen in Osteoarthritis, Knee, this one is the 9th largest by enrollment, is the only one that started in 2018, is the only one in phase 2, and was the 9th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

None of the 11 studies testing acetaminophen in Osteoarthritis, Knee is open now. The open studies under Osteoarthritis, Knee, anywhere →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing acetaminophen in Osteoarthritis, Knee as a file.
02

Study summary

Osteoarthritis is a common, chronic, progressive, skeletal, degenerative disorder that frequently affects several joints such as knee, hip, spine and hands.This placebo-controlled clinical trial assessed the effects of naproxen sodium, acetaminophen and celecoxib on stiffness in subjects with osteoarthritis.

Read the detailed description

The primary objective of the study was to assess the responsiveness of the Brief Arthritis Stiffness Scale (BASS) for detecting treatment effects of common over-the-counter (OTC) analgesics and a common prescription analgesic in subjects with knee osteoarthritis.

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 40 and 80 years
  • (BMI) between 18 and \<40 kg/m\^2
  • Unilateral or bilateral osteoarthritis of the knee
  • Diagnostic quality radiography of the target knee performed no more than 1 year prior to baseline showing evidence of osteoarthritis (OA) with Kellgren and Lawrence grade of II or III
  • Joint Stiffness Severity score ≥3.0 on a 0-10 numerical rating scale (NRS) at screening

Exclusion criteria

Exclusion Criteria:

  • History of underlying inflammatory arthropathy, rheumatoid arthritis or fibromyalgia
  • History of or scheduled for target knee replacement surgery
  • Recent injury in target knee (past 4 months)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Treatment A-D-C-B

    Participants received naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by placebo for 4 days; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.

    Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetaminophen ER · Drug: Celecoxib · Drug: Placebo

  • Experimental
    Treatment B-C-D-A

    Participants received acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by placebo for 4 days; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.

    Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetaminophen ER · Drug: Celecoxib · Drug: Placebo

  • Experimental
    Treatment C-A-B-D

    Participants received celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by placebo for 4 days. Treatment periods were separated by a washout period of 3 to 7 days.

    Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetaminophen ER · Drug: Celecoxib · Drug: Placebo

  • Experimental
    Treatment D-B-A-C

    Participants received placebo for 4 days; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days

    Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetaminophen ER · Drug: Celecoxib · Drug: Placebo

Interventions

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)

  • DrugAcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)

  • 200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)

  • DrugPlacebo

    Over-encapsulation capsule, 4 days, oral (Treatment D)

06

What researchers measure

Primary outcomes

  1. Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period

    Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness. This endpoint was calculated by summing the changes from baseline (CFB) in BASS scores at Days 2, 3, and 4 of the treatment periods.

    Time frame: 4 days

Secondary outcomes

  1. Absolute Brief Arthritis Stiffness Scale (BASS) Score at Each Time Point

    Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness.

    Time frame: 4 days

  2. Change From Baseline in Brief Arthritis Stiffness Scale (BASS) Score at Day 4

    Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness.

    Time frame: Day 4

07

Results

Posted Jun 19, 2020

Participant flow

Study was conducted at multiple centers in the US between 29 June 2018 (first participant first visit) and 14 June 2019 (last participant last visit).

Participant flow — Overall Study
MilestoneTreatment A-D-C-BTreatment B-C-D-ATreatment C-A-B-DTreatment D-B-A-C
Started10101110
Completed1010109
Not completed0011
Withdrew: Non-compliance with study drug0010
Withdrew: Adverse event0001

Outcome measures

PrimarySum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period

Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness. This endpoint was calculated by summing the changes from baseline (CFB) in BASS scores at Days 2, 3, and 4 of the treatment periods.

Time frame:
4 days
Reported as:
Least squares mean · Scores on a scale
Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period
Scores on a scaleNaproxenAcetaminophen ERCelecoxibPlacebo
Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period-12.6 ± 5.46-13.6 ± 5.46-11.7 ± 5.46-2.3 ± 5.47
SecondaryAbsolute Brief Arthritis Stiffness Scale (BASS) Score at Each Time Point

Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness.

Time frame:
4 days
Reported as:
Least squares mean · Scores on a scale
Absolute Brief Arthritis Stiffness Scale (BASS) Score at Each Time Point
Scores on a scaleNaproxenAcetaminophen ERCelecoxibPlacebo
Day 123.0 ± 1.8423.3 ± 1.8424.6 ± 1.8422.6 ± 1.85
Day 220.8 ± 1.6219.7 ± 1.6220.6 ± 1.6223.2 ± 1.62
Day 318.4 ± 1.9718.4 ± 1.9718.9 ± 1.9822.4 ± 1.98
Day 418.1 ± 1.9718.0 ± 1.9718.5 ± 1.9722.0 ± 1.97
SecondaryChange From Baseline in Brief Arthritis Stiffness Scale (BASS) Score at Day 4

Brief Arthritis Stiffness Scale (BASS) is a patient-reported outcome (PRO) instrument measuring of the severity of osteoarthritis-related stiffness in the target knee joint. The BASS score ranges from 0 to 40 and a higher score indicates worse stiffness.

Time frame:
Day 4
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Brief Arthritis Stiffness Scale (BASS) Score at Day 4
Scores on a scaleNaproxenAcetaminophen ERCelecoxibPlacebo
Change From Baseline in Brief Arthritis Stiffness Scale (BASS) Score at Day 4-5.2 ± 1.97-5.3 ± 1.97-4.8 ± 1.97-1.3 ± 1.97

Adverse events

Collected over After the first dose of the investigational medicinal product (IMP) until the end of the treatment phase, up to 37 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen0/39 (0%)0/39 (0%)5/39 (12.8%)
Acetaminophen ER0/40 (0%)0/40 (0%)8/40 (20%)
Celecoxib0/40 (0%)0/40 (0%)10/40 (25%)
Placebo0/39 (0%)0/39 (0%)3/39 (7.7%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventNaproxenAcetaminophen ERCelecoxibPlacebo
VomitingGastrointestinal disorders0/392/400/400/39
Abdominal distensionGastrointestinal disorders1/390/400/400/39
Abdominal painGastrointestinal disorders1/390/400/400/39
DiarrhoeaGastrointestinal disorders0/390/400/401/39
Dry mouthGastrointestinal disorders1/390/400/400/39
Faeces discolouredGastrointestinal disorders1/390/400/400/39
Upper respiratory tract infectionInfections and infestations0/390/401/401/39
Joint injuryInjury, poisoning and procedural complications1/390/400/400/39
Heart rate decreasedInvestigations1/390/400/400/39
HeadacheNervous system disorders1/391/401/401/39

Baseline characteristics

Safety population: all participants who received at least one dose of investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(Years)Treatment A-D-C-BTreatment B-C-D-ATreatment C-A-B-DTreatment D-B-A-CTotal
Mean62.4 ± 9.2061.3 ± 8.7761.6 ± 7.5559.6 ± 8.2861.2 ± 8.19
Sex: Female, Male
Sex: Female, Male(Participants)Treatment A-D-C-BTreatment B-C-D-ATreatment C-A-B-DTreatment D-B-A-CTotal
Female9611733
Male14038
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment A-D-C-BTreatment B-C-D-ATreatment C-A-B-DTreatment D-B-A-CTotal
Hispanic or Latino10214
Not Hispanic or Latino9109937
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment A-D-C-BTreatment B-C-D-ATreatment C-A-B-DTreatment D-B-A-CTotal
American Indian or Alaska Native00101
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American452516
White658524
More than one race00000
Unknown or Not Reported00000
Brief Arthritis Stiffness Scale (BASS)
Brief Arthritis Stiffness Scale (BASS)(Scores on a scale)Treatment A-D-C-BTreatment B-C-D-ATreatment C-A-B-DTreatment D-B-A-CTotal
Treatment period 126.7 ± 4.9025.8 ± 5.0527.8 ± 5.5623.1 ± 5.3526.0 ± 5.31
Treatment period 225.8 ± 7.7421.8 ± 8.3222.3 ± 9.7425.3 ± 4.6423.8 ± 7.74
Treatment period 326.3 ± 5.5617.7 ± 10.0322.9 ± 10.2924.0 ± 6.4822.7 ± 8.69
Treatment period 421.9 ± 10.5620.3 ± 6.4024.2 ± 9.9523.8 ± 7.9222.5 ± 8.68
08

Study locations

5 sites
  • Radiant Research, Inc.
    Chandler, Arizona 85224, United States
  • Radiant Research, Inc.
    Pinellas Park, Florida 33781, United States
  • Radiant Research, Inc.
    Chicago, Illinois 60602, United States
  • Radiant Research, Inc.
    Cincinnati, Ohio 45236, United States
  • Radiant Research, Inc.
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jun 2019, 11 months.

Results were first posted in Jun 2020, 1 year after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 11 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2018
First posted
Jun 27, 2018
StartActual
Jun 29, 2018
Primary completionActual
Jun 14, 2019
CompletionActual
Jun 14, 2019
Results first posted
Jun 19, 2020
Last update
Jun 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03570554
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 27, 2018
Start date
Jun 29, 2018
Primary completion
Jun 14, 2019
Completion
Jun 14, 2019
Results posted
Jun 19, 2020
Last update
Jun 19, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naproxen · Acetaminophen · Celecoxib

Start the discussion